Anthem and Blue Cross Blue Shield plans are administered by individual state BCBS organizations under the BCBS Association umbrella. This means coverage varies state-to-state and plan-to-plan more than most carriers.
Type 2 diabetes coverage
Generally covered for T2D. Typical copay $25–$100/month with PA.
Weight management coverage
Highly variable by state. Some state BCBS plans cover Wegovy and Zepbound for weight indication; others exclude. Check your specific plan documents.
Cardiovascular indication coverage
Coverage of Wegovy under March 2024 CV indication expanding. Coverage varies by state plan.
OSA indication coverage
Coverage of Zepbound for OSA expanding across state plans through 2026.
Prior authorization criteria (typical)
Typical PA: BMI thresholds (≥30 or ≥27 with comorbidity); documented lifestyle modification; comorbidity documentation.
If your plan excludes weight-management drugs
Verify with your specific state BCBS plan; appeal denials; consider cash-pay compounded as alternative.
How to verify
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
Cash-pay alternative
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. NexLife, our editorial pick, lists compounded semaglutide at $95–$109 and tirzepatide at $115–$129 a month depending on plan length (prices as of November 6, 2026); see the NexLife review.